Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCP-IL-22BP mRNA in Advanced Malignant Solid Tumors
NCT07562815Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of NCP-IL22BP mRNA in solid tumor (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of Dose-Limiting Toxicities at 3 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
NCP-IL22BP mRNA
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07562815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562815.